Your browser doesn't support javascript.
loading
Effectiveness of inactivated influenza and COVID-19 vaccines in hospitalized children in 2022/23 season in Japan - The first season of co-circulation of influenza and COVID-19.
Shinjoh, Masayoshi; Furuichi, Munehiro; Tsuzuki, Shinya; Iqbal, Asef; Fukushima, Naoya; Soen, Sachiko; Fukushima, Hiroyuki; Kobayashi, Ken; Yamada, Go; Narabayashi, Atsushi; Tsunematsu, Kenichiro; Maeda, Naonori; Shimoyamada, Motoko; Yoshida, Makoto; Kuramochi, Yuu; Shibata, Akimichi; Yamaguchi, Yoshio; Yaginuma, Mizuki; Takahashi, Takao; Ishikane, Masahiro; Sugaya, Norio.
Afiliação
  • Shinjoh M; Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan; Division of Infectious Diseases and Infection Control, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan; Keio Pediatric Influenza Research Group,
  • Furuichi M; Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Electronic address: furuichi-mm@keio.jp.
  • Tsuzuki S; Disease Control and Prevention Center, AMR Clinical Reference Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan. Electronic address: stsuzuki@hosp.ncgm.go.jp.
  • Iqbal A; Department of Pediatrics, National Hospital Organization, Saitama Hospital, 2-1 Suwa, Wako-shi, Saitama 351-0102, Japan. Electronic address: asef.iqbal.24@gmail.com.
  • Fukushima N; Department of Pediatrics, Hiratsuka City Hospital, 1-19-1 Minamihara, Hiratsuka, Kanagawa 254-0065, Japan. Electronic address: naofuku0401@gmail.com.
  • Soen S; Department of Pediatrics, Tokyo Metropolitan Otsuka Hospital, 2-8-1 Minamiotsuka, Toshima-ku, Tokyo 170-8476, Japan. Electronic address: sachiko_soen0319@yahoo.co.jp.
  • Fukushima H; Department of Pediatrics, Tokyo Dental College Ichikawa General Hospital, 5-11-13 Sugano Ichikawa, Chiba 272-0824, Japan. Electronic address: fuku-h@keio.jp.
  • Kobayashi K; Department of Pediatrics, Yokohama Municipal Citizen's Hospital, 1-1 Mitsuzawanishimachi, Kanagawa-ku, Yokohama, 221-0855 Kanagawa, Japan. Electronic address: le.petit.oeuf.26@gmail.com.
  • Yamada G; Department of Pediatrics, Kawasaki Municipal Hospital, 12-1 Shinkawadori, Kawasaki-ku, Kawasaki, Kanagawa 210-0013, Japan. Electronic address: yamago.0414time@gmail.com.
  • Narabayashi A; Department of Pediatrics, Kawasaki Municipal Hospital, 12-1 Shinkawadori, Kawasaki-ku, Kawasaki, Kanagawa 210-0013, Japan. Electronic address: naraba@keio.jp.
  • Tsunematsu K; Department of Pediatrics, Hino Municipal Hospital, 4-3-1 Tamadaira, Hino-shi, Tokyo 191-0061, Japan. Electronic address: ktsune0605@yahoo.co.jp.
  • Maeda N; Department of Pediatrics, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo 152-8902, Japan. Electronic address: naonorimaeda27@gmail.com.
  • Shimoyamada M; Department of Pediatrics, Saitama City Hospital, 2460 Mimuro, Midori-ku, Saitama-shi, Saitama 336-0911, Japan. Electronic address: mochikodamochio@yahoo.co.jp.
  • Yoshida M; Department of Pediatrics, Sano Kosei General Hospital, 1728 Horigome-chou, Sano-city, Tochigi 327-8511, Japan. Electronic address: yoshimako0731@yahoo.co.jp.
  • Kuramochi Y; Department of Pediatrics, Ota Memorial Hospital, 455-1 Ohshimacho, Ota City, Gunma 273-8585, Japan. Electronic address: ykura123@gmail.com.
  • Shibata A; Department of Pediatrics, Japanese Red Cross Ashikaga Hospital, 284-1 Yobe-cho, Ashikaga, Tochigi 326-0843, Japan. Electronic address: helloakimichi@yahoo.co.jp.
  • Yamaguchi Y; Department of Clinical Research, Department of Infection and Allergy, National Hospital Organization Tochigi Medical Center, 1-10-37 Nakatomaturi, Utsunomiya-City, Tochigi 320-8580, Japan. Electronic address: yoyamaguchitochigimc@gmail.com.
  • Yaginuma M; Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Electronic address: yaginumamizuki@gmail.com.
  • Takahashi T; Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Electronic address: ttakahashi@keio.jp.
  • Ishikane M; Disease Control and Prevention Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan. Electronic address: ishikanemasahiro@gmail.com.
  • Sugaya N; Keio Pediatric Influenza Research Group, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Electronic address: sugaya47@gmail.com.
Vaccine ; 41(33): 4777-4781, 2023 07 25.
Article em En | MEDLINE | ID: mdl-37419851
We have analyzed the inactivated vaccine effectiveness (VE)for preventing influenza hospitalization by test-negative design in the 2022/23 season. This is the first season of co-circulation of influenza and COVID-19, and a unique period because all inpatients received COVID-19 screening. Among 536 children hospitalized with fever, none were positive for both influenza and SARS-CoV-2. The adjusted VE for preventing influenza A for all children, the 6-12-year-old group, and those with underlying diseases was 34 % (95 %CI, -16 %-61 %, n = 474), 76 % (95 % CI, 21 %-92 %, n = 81), and 92 % (95 % CI, 30 %-99 %, n = 86), respectively. Only 1 out of 35 hospitalized cases with COVID-19, and 42 out of 429 controls, had been immunized with COVID-19 vaccine. This is the first report showing influenza VE by age group in children in this limited season. We still recommend the inactivated influenza vaccine for children based on the significant VE in subgroup analysis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Influenza Humana / COVID-19 Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Child / Humans País/Região como assunto: Asia Idioma: En Revista: Vaccine Ano de publicação: 2023 Tipo de documento: Article País de publicação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra Influenza / Influenza Humana / COVID-19 Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Child / Humans País/Região como assunto: Asia Idioma: En Revista: Vaccine Ano de publicação: 2023 Tipo de documento: Article País de publicação: Holanda